Peptic Ulcer Is the Most Common Cause of Non-Variceal Upper-Gastrointestinal Bleeding (NVUGIB) in China

Mingliang Lu, Gang Sun, Xiao-Mei Zhang, You-Qing Xv, Shi-Yao Chen, Xiao-Liang Li, Bin Lv, Jian-Lin Ren, Xue-Qing Chen, Hui Zhang, Chen Mo, Yan-Zhi Wang, Yun-Sheng Yang

Corresponding Author: Yun-Sheng Yang, e-mail: sunny301ddc@126.com
Source of support: Hundreds of Young and Middle-Aged Academic and Technical Backbone Projects in Kunming Medical University (Grant No. 60117190431) and Grant Major Scientific Research Projects of Ministry of Health Industry (Grant No. 201002020)

Background: This study aimed to discover the common cause of non-variceal upper-gastrointestinal bleeding (NVUGIB) by conducting a multi-center retrospective study from 2008 to 2012.

Material/Methods: Hospitalized patients ages ≥18 years old, from 8 hospitals in China, diagnosed with NVUGIB by endoscopy from 1 January 2008 to 31 December 2012 were enrolled. Questionnaires were developed and a data-entry graphical user interface was designed by using EpiData software.

Results: Total of 2977 hospitalized patients from 8 medical centers were included. A total of 95.47% (2842/2977) of patients were admitted to a general ward, 3.53% (105/2977) were admitted to an emergency ward, and 1.00% (31/2977) were admitted to an intensive care unit. Peptic ulcer remained the most common cause of NVUGIB (73.26%), but there was a declining trend in its constituent ratio, from 2008 to 2012. A total of 14.41% (429/2977) of patients had co-morbid conditions, 92.85% (2764/2977) used proton-pump inhibitors (PPIs) prior to endoscopic treatment, 19.65% (585/2977) underwent emergency endoscopy, and 23.45% (698/2977) received a transfusion of red blood cell suspensions. A total of 5.34% (159/2977) underwent endoscopic therapy, with a treatment rate of 16.9% in high-risk peptic ulcer patients (96/568). A total of 7.69% (237/2977) were administered aspirin, of whom 32.50% (77/237) resumed aspirin intake after gastrointestinal bleeding was controlled. The median length of hospitalization was 8 days (IQR, 5–11) and the mortality rate was 1.71% (51/2977).

Conclusions: Peptic ulcer was still the most common cause of NVUGIB in China. The proportion of patients with high-risk peptic ulcer bleeding who received endoscopic therapy was 16.9%. Only 19.65% of NVUGIB patients underwent emergency endoscopy.

MeSH Keywords: Blood Transfusion • Gastrointestinal Diseases • Non-Variceal Upper-Gastrointestinal Bleeding

Full-text PDF: https://www.medscimonit.com/abstract/index/idArt/909560
Background
Non-variceal upper gastrointestinal bleeding (NVUGIB) refers to diseases of the digestive tract above the ligament of Treitz. Studies in Western countries showed that the incidence rate of NVUGIB is 20–60/100,000 and is particularly high among elderly patients with other systemic diseases, with a mortality rate for NVUGIB of about 7–14% [1–4]. Retrospective large-sample studies on the epidemiologic characteristics and clinical therapy status of NVUGIB have been conducted in Western countries. Peptic ulcer is still the primary cause of NVUGIB. The rate of surgery, length of hospitalization, and mortality rate have declined compared with previous years [5,6]. The incidence rate of peptic ulcer has been reduced with the help of oral proton-pump inhibitors (PPIs) and Helicobacter pylori eradication therapy. However, NVUGIB remains a common and clinically severe acute disease [7] with a re-bleeding rate of around 10% [8]. The use of anti-platelet agents to prevent cardiovascular and cerebrovascular diseases and the use of non-steroidal anti-inflammatory drugs (NSAIDs) for the treatment of various bone and joint diseases are increasing in parallel with socioeconomic development and the advent of an aging society. Since the incidence rate of upper gastrointestinal bleeding induced by the use of aspirin, anticoagulants, and NSAIDs is increasing, the proportion of elderly people with comorbid diseases is also increasing. However, the data on this remain unclear in China. Therefore, this study aimed to discover the most common causes of non-variceal, upper gastrointestinal bleeding (NVUGIB) by conducting a multi-center retrospective study from 2008 to 2012. This study also aimed to understand the epidemiologic characteristics, diagnostic and etiologic make up, endoscopic therapy, re-bleeding rate, rates of surgery and angiographic embolization, in-hospital mortality rate, and length of hospitalization in NVUGIB patients, as well as the other clinical issues.

Material and Methods
Study subjects

A total of 8 hospitals participated, and 2977 hospitalized patients endoscopically diagnosed with NVUGIB from 1 January 2008 to 31 December 2012 were included. The present study was approved by the Ethics Committee of the Chinese PLA General Hospital, Beijing, China.

Definitions

Definition: NVUGIB refers to non-variceal diseases of the digestive tract above the ligament of Treitz, including bleeding of the pancreatic or bile ducts, and bleeding proximal to the anastomosis after gastrojejunostomy. Adherent clots are blood clots that adhere to the surface of an ulcer. Hematemesis refers to vomiting of fresh blood or blood clots. Coffee ground refers to coffee ground vomiting that was confirmed positive by vomit occult blood test. Melena refers to tarry stools confirmed by a physician or nurse. Re-bleeding refers to recurrence of hematemesis, bloody stool, persistent hypotension/tachycardia, and progressive decline in hemoglobin levels after the first endoscopic diagnosis or therapy. Diagnosis by endoscopy includes esophageal ulcer, gastric cystic lesions, ectopic pancreas, gastric mucosal lesions in portal hypertension, duodenal inflammation, Henoch-Schönlein purpura (abdominal), angiodysplasia with hemorrhage, and hemorrhage after endoscopic therapy (various types of bleeding due to endoscopic therapy). Ischemic heart disease (IHD) includes conditions that patients previously had, such as myocardial infarction, angina, and arrhythmias, or coronary artery bypass grafting. Cardiac failure includes cardiac failure Class I, II, III, and IV, as per the New York Heart Association (NYHA) Functional Classification. Chronic obstructive pulmonary disease (COPD) refers to chronic bronchitis and emphysema with persistent airflow limitation determined by pulmonary function tests (PFTs). Cancer includes patients with advanced malignant tumors in various body systems within 12 months after surgery, as well as those whose metastasis cannot be treated with surgery. Renal disease refers to renal failure that had been diagnosed previously. Central nervous system disease refers to patients with a history of cerebral hemorrhage or infarction. Arthritis includes rheumatism/rheumatoid arthritis, osteoarthritis, and gouty arthritis.

Inclusion and exclusion criteria

Inclusion criteria were all hospitalized patients, aged ≥18 years old, diagnosed with NVUGIB by endoscopy (including newly admitted patients and those with NVUGIB occurring during hospitalization), diagnostically confirmed by endoscopy, and with at least 1 of the following clinical symptoms: (1) hematemesis and/or melena, (2) Drainage of coffee grounds or fresh blood in the gastric tube, (3) Positive fecal occult blood test (FOBT), and (4) Presence of varices, but endoscopy confirmed that bleeding was unrelated to varices.

Exclusion criteria were variceal bleeding and lower-gastrointestinal bleeding.

Data processing

EpiData entry software (version 3.1, EpiData Association, Odense, Denmark) was used to convert the questionnaire into a data-entry graphical user interface (GUI) that was consistent with the survey form. The data entry was controlled by two-pass verification on all collected data to ensure the quality of data entered. All collected data were classified and aggregated according to the needs of the survey, and the researchers were
Statistical analysis

SPSS software (version 17.0, SPSS, Chicago, IL, USA) was used for all statistical analyses in this study. The characteristics and clinical demographic and epidemiologic features were analyzed by using a descriptive statistical method (mean ± standard deviation (SD), percentage, median, and interquartile range [IQR]). Univariate analysis for risk factors affecting mortality was performed by using the Pearson χ² test, and p<0.05 variables were incorporated into the multivariate analysis model; clinically significant factors were also incorporated into the multivariate analysis model, even if there was no statistically significant difference. The stepwise logistic regression model was used to perform multivariate analysis of factors affecting mortality, and p<0.05 was considered to indicate a statistically significant difference.

Table 1. Patient’s characteristics.

| Variable                  | Value (n=2,977), % (n)       |
|---------------------------|------------------------------|
| Gender                    |                              |
| Male                      | 76.486 (2,277)               |
| Female                    | 23.514 (700)                 |
| Age years                 |                              |
| Median (IQR)              | 55 (40–68)                   |
| Mean (SD)                 | 54.645±14.3418               |
| Age group distribution    |                              |
| <60                       | 59.489 (1,771)               |
| 60–79                     | 33.557 (999)                 |
| ≥80                       | 6.953 (207)                  |
| Education background      |                              |
| Illiteracy                | 4.736 (141)                  |
| Primary education         | 14.108 (420)                 |
| Junior middle school education | 24.118 (718)          |
| High school graduate      | 26.402 (786)                 |
| Bachelor's degree         | 12.361 (368)                 |
| Master’s or Doctoral degree | 1.31 (39)                   |
| Not recorded              | 16.963 (505)                 |
| Type of ward              |                              |
| General ward              | 95.465 (2,842)               |
| Emergency ward            | 3.527 (105)                  |
| ICU                       | 1.007 (30)                   |
| Hemoglobin concentration(g/L) |                          |
| <10                       | 33.557 (999)                 |
| 10–100                    | 27.8 (827)                   |
| 51–70                     | 15.217 (453)                 |
| ≤70                       | 23.446 (690)                 |
| Hemodynamic status        |                              |
| Normal (BP>100, HR<100)   | 77.09 (2,295)                |
| Tachycardia only (HR<100) | 19.17 (573)                  |
| 70< BP ≤100               | 13.369 (398)                 |
| 50< BP ≤70                | 0.269 (8)                    |
| BP ≤50                    | 0.1 (3)                      |

Table 1. Patient’s characteristics.

| Variable                  | Value (n=2,977), % (n)       |
|---------------------------|------------------------------|
| Variable                  | Value (n=2,977), % (n)       |
| Urea mmol/L               |                              |
| <3.0                      | 4.199 (125)                  |
| 3.0–6.9                   | 43.87 (1,306)                |
| 7.0–11.9                  | 28.720 (855)                 |
| 12.0–19.9                 | 12.999 (387)                 |
| ≥20.0                     | 3.325 (99)                   |
| Not recorded              | 6.886 (205)                  |
| Median urea (IQR)         | 6.78 (4.75–10.14)            |
| Medication at presentation|                              |
| Clopidogrel               | 0.672 (20)                   |
| Aspirin + Clopidogrel     | 1.579 (47)                   |
| Warfarin                  | 0.638 (19)                   |
| NSAID                     | 1.108 (33)                   |
| LMWH                      | 0.1 (3)                      |
| Comorbidty (%)            |                              |
| IHD                       | 3.964 (118)                  |
| Cardiac failure           | 0.168 (5)                    |
| COPD                      | 0.974 (29)                   |
| Renal disease             | 0.974 (29)                   |
| CNS disease               | 0.638 (19)                   |
| Arthritis                 | 2.519 (75)                   |
| Two or more Comorbidities | 2.519 (75)                   |
| Other                     |                              |
| Smoking history           | 28.96 (862)                  |
| History of drinking       | 20.96 (619)                  |
| History of upper gastrointestinal bleeding | 12.832 (382) |

BP – systolic blood pressure (mm Hg); HR – heart rate/min; LMWH – low molecular weight heparin; NSAID – non-steroidal anti-inflammatory drug.
Results

A total of 8 hospitals participated and 2977 patients were included in this study. The median age of the patients was 55 years old (range, 40–68 years old), the average age was 54.65±14.34 years, and the male: female ratio was 3.25:1.

Patient characteristics and drug use

Patient characteristics included age distribution, education levels, type of ward, medication history, laboratory tests, hemodynamics, Rockall score, and Blatchford score (Table 1). The median time from the onset of clinical symptoms to hospitalization was 48 h (IQR, 24–72). The proportion of patients administered PPIs prior to endoscopy was 92.85% (2764/2977); 18.95% (564/2977) were administered tranexamic acid to stop bleeding, of whom 11.52% (65/564) had different degrees of coagulation dysfunction. A total 1.24% (37/2977) of patients had a history of erythromycin intake, 0.30% (9/2977) were administered metoclopramide hydrochloride to improve the rate of endoscopic diagnosis, and 1.11% (33/2977) were administered NSAIDs. A total of 237 patients took aspirin prior to treatment, of whom 32.50% (77/237) resumed aspirin intake after the gastrointestinal bleeding was controlled; the average time until the resumption of intake was 25.92±11.31 days (5–60 days). A total of 0.91% (27/277) of the patients used a long-term oral PPI for NSAID prophylaxis and the potential risks of bleeding caused by anti-platelet drugs. The clinical presentations of different age groups are summarized in Table 2.

Table 2. Clinical presentation by age group.

| Clinical presentation | Age <60 (1,771) | Age 60–79 (999) | Age ≥80 (207) |
|-----------------------|----------------|----------------|-------------|
|                       | %, (n)         | %, (n)         | %, (n)      |
| OB(+)                 | 3.444 (61)     | 5.205 (52)     | 3.865 (8)   |
| Melena alone          | 61.999 (1098)  | 54.354 (543)   | 49.758 (103) |
| Hematemesis alone     | 10.107 (179)   | 15.315 (153)   | 18.841 (39) |
| Hematemesis & melena  | 24.280 (430)   | 24.224 (242)   | 21.739 (45) |
| Coffee ground emesis or blood from NG tube | 0.169 (3) | 0.9 (9) | 5.797 (12) |

OB(+) – fecal occult blood is positive.

Table 3. Endoscopic diagnoses by age group.

| Endoscopic diagnoses | Age <60 (1,771) | Age 60–79 (999) | Age ≥80 (207) |
|----------------------|----------------|----------------|-------------|
|                       | %, (n)         | %, (n)         | %, (n)      |
| Peptic ulcer         | 80.632 (1428)  | 64.965 (649)   | 50.242 (104) |
| Malignancy           | 4.122 (73)     | 10.11 (101)    | 9.662 (20)  |
| Esophagitis          | 4.009 (71)     | 5.706 (57)     | 5.314 (11)  |
| Acute gastric mucosal lesions | 3.106 (55) | 4.104 (41) | 10.145 (21) |
| Mallory-Weiss        | 2.315 (41)     | 2.503 (25)     | 2.899 (6)   |
| Dieulafoy lesions    | 1.016 (18)     | 0.9 (9)        | 0.483 (1)   |
| Anastomotic bleeding | 1.863 (33)     | 3.303 (33)     | 2.415 (5)   |
| Other                | 1.073 (19)     | 5.706 (57)     | 16.908 (35) |
| No abnormality found | 1.863 (33)     | 2.703 (27)     | 1.932 (4)   |

Diagnosis

A total of 19.65% (585/2977) of patients underwent emergency endoscopy and the median time from gastrointestinal bleeding to gastroscopy was 72 h (36–120 h). The endoscopy waiting time for the patients with peptic ulcer was 3.9±1.2 days. Peptic ulcer was the most common cause of NVUGIB (73.26%). A total of 6.52% (194/2977) of the cases were neoplastic lesions and 3.93% (117/2977) were acute gastric mucosal lesions (Table 3), of whom 19.66% (23/117) used aspirin and 4.27% (5/117) used aspirin and clopidogrel simultaneously.
The trends of peptic ulcer, tumor, and acute gastric mucosal lesions from 2008 to 2012 (5 years) are shown in Figure 1.

Blood transfusion

A total of 23.45% (698/2977) of patients received a transfusion of red blood cell suspension. Every patient received an average of 5.33±6.53 units of blood transfused. Moreover, the average hemoglobin level for the patients before the transfusion was 65.62±16.30 g/l.

Endoscopic therapy

A total of 5.34% (159/2977) of patients underwent endoscopic therapy, of whom 27.04% (43/159) underwent endoscopic combined therapy (Table 4). A total of 19.08% (568/2977) of patients had high-risk peptic ulcer bleeding (Table 5). A total of 159 patients had adherent clots. Ten patients underwent rinsing and subsequent exposure of basal lesions with physiological saline solution, of whom 2 patients had active ejection of blood, 4 had active errhysis, 1 had a vascular stump, and 3 had a fibrin-covered clean ulcer base. The patients were divided into 3 groups based on endoscopy waiting time: ≤24 h, 24–96 h, and ≥96 h. Our study showed that the frequency of endoscopic therapy in the ≤24 h group was higher than that in the 24–96 h and ≥96 h groups (p<0.05) (Table 6). There was no statistically significant difference in the length of hospitalization between the 3 groups (10.13±11.82, 8.87±7.31, and 9.64±7.33 days, respectively, p=0.92).

Re-bleeding

A total of 2.92% (87/2,977) of patients had re-bleeding. The patients were divided into ≤24 h, 24–96 h, and ≥96 h groups by endoscopy waiting time. Our study showed that the rates of re-bleeding in the ≤24 h group and 24–96 h group were higher than in the ≥96 h group (p<0.05), while there was no statistically significant difference between the ≤24 h group and 24–96 h group (Table 7). A further analysis found that the proportions of high-risk peptic ulcer bleeding in each group of patients with peptic ulcer were 288 (74%), 182 (23%), and 98 (10%), respectively (p<0.05). The average time from re-bleeding to the first endoscopic therapy was 49.61±53.45 h. A total of 4.60% (4/87) of patients were treated with medication and blood transfusion, 12.64% (11/87) of these underwent a second endoscopic treatment, 17.24% (15/87) underwent embolization, and 65.52% (57/87) underwent surgery, while a total of 7 patients (8.05%) died.

Angiographic intervention embolization

The proportion of patients undergoing angiographic embolization was 0.50% (15/2977), of whom 9 were found to have bleeding vessels (including 4 cases of the gastroduodenal artery, 3 of the pancreaticoduodenal artery, 1 of the dorsal pancreatic artery supplying the duodenum, and 1 of the short gastric arteries of the splenic artery) and underwent embolization, with 7 cases of successful hemostasis (77.78%). The 6 patients without a bleeding blood vessel underwent preventive embolization

Table 4. Endoscopic therapy.

| Treatment method | n=159 (%) |
|------------------|-----------|
| Endoscopic drug delivery by aerosol spray for hemostasis | 24 (15.09) |
| Endoscopic injection of 1: 10,000 adrenaline | 43 (27.04) |
| High-frequency electrocoagulation | 2 (1.26) |
| Argon plasma coagulation | 11 (6.92) |
| Hemoclip | 36 (22.64) |
| Endoscopic injection of 1: 10,000 epinephrine + thermal coagulation (any of which) | 3 (1.89) |
| Endoscopic injection of 1: 10,000 epinephrine + Hemoclip | 37 (23.27) |
| Endoscopic injection of 1: 10,000 epinephrine + thermal coagulation (any of which) + Hemoclip | 3 (1.89) |
that involved the pancreatic artery, hepatic artery-left gastric artery, hepatic artery, left gastric artery, left gastric and right gastroepiploic artery, and gastroduodenal artery, respectively, with 4 cases of successful hemostasis (66.67%).

Surgery

The proportion of patients undergoing surgery was 2.65% (79/2977), with an average age of 56.22±13.82 years, including 72.15% (57/79) male patients, among whom 67.09% (53/79) had tumors, 25.32% (20/79) had hemorrhage uncontrollable by medication or endoscopy, 3.80% (3/79) had vascular malformation, 2.53% (2/79) had uncontrollable bleeding caused by endoscopic therapy, and 1.27% (1/79) had an ectopic pancreas, with a postoperative mortality rate of 5.06% (4/79).

Comorbidities

The proportion of patients with comorbidities was 1.81% (54/2977) (Table 8). Among these comorbidities, 44.44% were pneumonia, 7.41% were cardiovascular events, 7.41% were liver failure, 18.52% were renal failure, 3.7% were stroke, 3.7% were deep vein thrombosis, 1.85% were perforation, 7.41% were pneumonia and renal failure, 1.85% were pneumonia and cardiovascular events, 1.85% were pneumonia and deep vein thrombosis, and 1.85% were cardiovascular events or liver and kidney failure. The results also showed that the pneumonia was the most frequently occurring comorbidity.

The length and costs of hospitalization

The median length of hospitalization was 8 days (IQR, 5–11), while the median cost of hospitalization was RMB 7363.55 (IQR, 4574.76–12521.37) and the median cost of endoscopy was RMB 330.00 (IQR, 250–430).

Multivariate analysis of mortality rate and factors associated with mortality

The mortality rate was 1.71% (51/2977), of whom 37.25% (19/51) completed endoscopy within 24 h and 25.49% (13/51) developed comorbidities. According to the results in Tables 9 and 10, the most significant risk factors associated with mortality were: age (p=0.0000), type of ward (p=0.0049), blood pressure level (p=0.0000), comorbidity (p=0.0000), endoscopy waiting time (p=0.0000), and re-bleeding (p=0.0008).
### Table 8. Comorbidities of the patients.

| Complication (comorbidity) | n=54 (%) |
|----------------------------|----------|
| Pneumonia                  | 24 (44.44) |
| Cardiovascular events      | 4 (7.41) |
| Liver failure              | 4 (7.41) |
| Renal failure              | 10 (18.52) |
| Stroke                     | 2 (3.70) |
| Deep vein thrombosis       | 2 (3.70) |
| Perforation                | 1 (1.85) |
| Pneumonia and renal failure| 4 (7.41) |
| Pneumonia and cardiovascular events | 1 (1.85) |
| Pneumonia and deep vein thrombosis | 1 (1.85) |
| Cardiovascular events, and liver and kidney failure | 1 (1.85) |

### Table 9. Univariate analyses for mortality.

| Variable                          | No. of patients | Mortality | χ² Value | p Value |
|-----------------------------------|-----------------|-----------|----------|---------|
|                                  | (n)             | No, n (%) | Yes, n (%) |         |
| Gender                           |                |           |           |         |
| Male                             | 2277           | 2,240 (98.38) | 37 (1.62) | 0.4473  | 0.5036  |
| Female                           | 700            | 686 (98.00) | 14 (2.00) |          |         |
| Age (years old)                  |                |           |           |         |
| <60                              | 1711           | 1,758 (99.77) | 13 (0.73) |          |         |
| 60–79                            | 999            | 978 (97.90) | 21 (2.10) |          |         |
| ≥80                              | 207            | 190 (91.79) | 17 (8.21) | 62.9121 | 0.0000  |
| Type of ward                     |                |           |           |         |
| General ward                     | 2842           | 2,798 (98.45) | 44 (1.55) | 39.8414 | 0.0000  |
| Emergency ward                   | 105            | 100 (95.24) | 5 (4.76)  |          |         |
| ICU                              | 30             | 28 (93.33)  | 2 (6.67)  | 10.6273 | 0.0049  |
| Hemoglobin (g/l)                 |                |           |           |         |
| >101                             | 999            | 986 (98.70) | 13 (1.30) |          |         |
| 81–100                           | 827            | 816 (96.67) | 11 (3.33) |          |         |
| 71–80                            | 453            | 444 (98.01) | 9 (1.99)  |          |         |
| ≤70                              | 698            | 680 (97.42) | 18 (2.58) | 5.0347  | 0.1693  |
| Blood circulation                |                |           |           |         |
| Normal (BP >100, HR <100)        | 2295           | 2,268 (98.82) | 27 (1.18) |          |         |
| Tachycardia (HR >100)            | 273            | 265 (97.07) | 8 (2.93)  |          |         |
| 70≤ BP <100                      | 198            | 184 (96.48) | 14 (3.52) |          |         |
| 50≤ BP <70                       | 8              | 6 (75.00)   | 2 (25.00) |          |         |
| BP <50                           | 3              | 3 (100.00)  | 0 (0.00)  | 3 (100.00) | 0.0000  |

This work is licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
Discussion

In this nationwide, multi-center, retrospective study, we developed a preliminary understanding of the status of NVUGIB in China, and identified some issues and differences compared with Western studies. In this survey, the average age of the patients was 54.65±14.34 years old and the proportion of patients aged over 80 years old was 6.95%, which was lower than that of previous studies from the West [6,8–10]. Our study found that more than half of the total patients had middle and high school education levels, more than 95% were admitted to general wards, and 12.83% had a history of upper-gastrointestinal bleeding, which was slightly lower than that reported in Portugal [10]. Clinical symptoms were dominated by melena, which accounted for 58.58% of patients, higher than that reported by Zeitoun et al. [11]. The proportion of patients with a comorbidity was 14.41%, of which ischemic heart disease was the most common complication. In addition, central nervous system diseases and tumors were common co-morbidities, and 22.91% of the patients had hemodynamic instability. Our study indicated that 58.45% (1740/2977) of patients had a completed Rockall score and 60.46% (1800/2977) had a Blatchford score. A total of 92.85% (2764/2977) of patients were administered PPIs prior to endoscopic examination. A total of 18.95% (564/2977) were administered tranexamic acid for hemostasis, of whom 11.52% (65/564) had varying degrees of coagulation disorders, while a higher proportion (88.48%) of the remaining patients had normal blood.

Table 9 continued. Univariate analyses for mortality.

| Variable                        | No. of patients | Mortality | χ² Value | p Value |
|---------------------------------|-----------------|-----------|----------|---------|
|                                | (n)             | No, n (%) | Yes, n (%)|         |
| Comorbidity (%)                 |                 |           |          |         |
| Ischemic heart disease          | 118             | 114       | 4        | 3.39    |
| Heart failure                   | 5               | 5         | 0        | 0.00    |
| COPD                            | 29              | 28        | 1        | 3.45    |
| Tumor                           | 86              | 77        | 9        | 10.47   |
| Kidney disease                  | 29              | 27        | 2        | 6.90    |
| Central nervous system diseases | 68              | 66        | 2        | 2.94    |
| Arthritis                       | 19              | 19        | 0        | 0.00    |
| >2 comorbidities                | 75              | 67        | 8        | 10.67   |
| No comorbidities                | 2548            | 2,523     | 25       | 0.98    | 91.0814 | 0.0000 |
| Time to endoscopy               |                 |           |          |         |
| ≤12 h                           | 199             | 197       | 2        | 1.01    |
| 12 h < T ≤24 h                  | 386             | 383       | 3        | 0.78    |
| >24 h                           | 2392            | 2,346     | 46       | 1.92    | 3.2269  | 0.1992 |
| Hemoglobin levels before transfusion |           |           |          |         |
| ≤70                             | 449             | 429       | 20       | 4.45    |
| 70< Hb ≤90                      | 187             | 175       | 12       | 6.42    |
| >90                             | 62              | 58        | 4        | 6.45    |
| No transfusion                  | 2279            | 2,264     | 15       | 0.66    | 67.9431 | 0.0000 |
| Rebleeding                      |                 |           |          |         |
| Yes                             | 87              | 81        | 6        | 6.9     |
| No                              | 2890            | 2,845     | 45       | 1.56    | 11.3050 | 0.0008 |

BP – blood pressure; Hb – hemoglobin.
coagulation. Meanwhile, a total of 237 patients took aspirin before treatment, of whom 32.50% (77/237) resumed aspirin intake after gastrointestinal bleeding was controlled; the average time to resumption of intake was 25.92±11.31 days (5–60 days), which is significantly different from a recent study in Japan [12] showing an average discontinuation period of 4.1±4.0 days for NVUGIB patients taking antithrombotic drugs, and from international consensus [1].

Previous studies [13–15] showed that endoscopy within 12 h did not improve the clinical prognosis. The 2011 Asia-Pacific Consensus [5] recommended a 24-h time frame for endoscopy, but it can be appropriately delayed for patients with severe cardiopulmonary dysfunction. Previous studies [16–18] show that failure to perform an endoscopy within 24 h may increase the mortality rate from 2.5% to 6.6%. Patients who did not undergo endoscopy were mostly aged over 80 years and had more than 3 comorbidities. This study found that 9.65% (585/2977) of patients underwent emergency endoscopy, with a median time from gastrointestinal bleeding to endoscopy of 72 h (36–120 h). We also divided the patients into £24 h, 24–96 h, and ≥96 h groups by the time to endoscopy and found that emergency endoscopy did not reduce the rate of re-bleeding. A further analysis found that a high proportion of patients

Table 10. Multivariate analysis of factors associated with mortality.

| Independent variable | OR value | 95% confidence interval | p Value |
|----------------------|----------|-------------------------|---------|
| **Age (years old)**  |          |                         |         |
| <60                  | 1.00     |                         |         |
| 60–79                | 2.49     | 1.180–5.241             | 0.0166  |
| ≥80                  | 11.00    | 4.799–25.237            | 0.0000  |
| **Type of ward**     |          |                         |         |
| General ward         | 1.00     |                         |         |
| Emergency ward       | 4.70     | 1.719–12.865            | 0.0026  |
| ICU                  | 3.15     | 0.835–11.534            | 0.1166  |
| Hemoglobin (g/l)     |          |                         |         |
| >100                 | 1.00     |                         |         |
| 81–100               | 1.05     | 0.450–2.450             | 0.9101  |
| 71–80                | 1.10     | 0.428–2.805             | 0.8480  |
| ≤70                  | 1.10     | 0.866–4.060             | 0.1166  |
| **Blood circulation**|          |                         |         |
| Normal (BP >100, HR <100) | 1.00  |                     |         |
| Tachycardia (HR >100) | 0.00     | 0.000–3.163             | 0.9638  |
| ICU                  | 2.67     | 1.041–6.866             | 0.0411  |
| 70≤ BP <100          | 2.81     | 1.343–5.898             | 0.0061  |
| 50≤ BP <70           | 2.81     | 0.866–4.060             | 0.0166  |
| BP <50               | 9.58     | 1.330–68.958            | 0.0249  |
| **Comorbidity**      |          |                         |         |
| No comorbidity       | 1.00     |                         |         |
| 1                    | 3.08     | 1.563–6.076             | 0.0012  |
| ≥2 comorbidities     | 7.71     | 3.016–19.699            | 0.0000  |
| **Time to endoscopy**|          |                         |         |
| >24 h                | 1.00     |                         |         |
| ≤24 h                | 0.34     | 0.180–0.659             | 0.0013  |
| **Rebleeding**       |          |                         |         |
| No                   | 1.00     |                         |         |
| Yes                  | 3.63     | 1.358–9.694             | 0.0101  |
in the emergency endoscopy group had high-risk peptic ulcer bleeding (Forrest Ia–IIb), which may be associated with the rate of re-bleeding. A study in Hong Kong [19] showed that the endoscopy waiting time for patients with peptic ulcer bleeding was 0.9±1.8 days, while the endoscopy waiting time in this study was 3.9±1.2 days. The lower proportion of emergency endoscopies and the longer endoscopy waiting time might be associated with the health care system in China, where critically ill patients are mostly concentrated in larger-scale hospitals that often require a longer waiting time for patient assessment and from examination to endoscopy, compared with that in Hong Kong and foreign countries. Peptic ulcer was still the most common cause of NVUGIB (73.26%), much higher than that reported in Western countries [4,20–22], and 61.71% (1346/2181) of patients underwent H. pylori testing. The incidence rate of peptic ulcer presented a declining trend each year from 2008 to 2012. The proportion of patients undergoing the transfusion of a red blood cell suspension was 23.45% (698/2977), which was lower than that reported in a previous study [5]. The average hemoglobin level prior to transfusion was 65.6±16.30 g/l. A randomized, controlled trial in Spain showed that a restrictive transfusion (Hb <70 g/l) can reduce the risk of re-bleeding, demand for salvage therapy, and comorbidities, as well as improve the survival rate [23].

A total of 5.34% (159/2977) of patients underwent endoscopic therapy, of whom 27.04% (43/159) underwent combination endoscopic therapy and 27.04% (43/159) only received endoscopic injection of 1: 10 000 adrenaline. The proportion of patients with high-risk peptic ulcer bleeding was 19.08% (568/2977), of whom 16.9% (96/568) underwent endoscopic therapy, which is less than that reported by a study in Portugal [10], while 6.34% (36/568) only received endoscopic injection of 1: 10 000 adrenaline and 4.58% (26/568) underwent combination endoscopic therapy. The treatment of adherent clots on the peptic ulcer remains controversial. In this study, only 6.29% (10/159) of patients received endoscopic lavage, including 7 patients who were found to have lesions and subsequently underwent endoscopic therapy. Hence, the pros and cons still require verification in a large-scale, randomized, controlled trial. Our study shows that 2.65% (79/2977) of patients received surgery, which was consistent with a study in the UK [5]. Such a low rate of surgery is attributed to recent advancements in endoscopic therapy. Surgery is often the last resort, with a higher mortality rate, and the postoperative mortality rate in this study was 5.06% (4/79). The proportion of patients undergoing angiographic embolization was 0.50% (15/2977), with a success rate of 77.78%, and the success rate of preventive embolization was 66.67% (4/6), which was consistent with that reported by Sildiroglu et al. [24]. The relatively low proportion of patients undergoing angiographic embolization is related to the technical requirement for equipment and expertise. A single-center retrospective study [25] showed that patients in the percutaneous intravascular embolization group were older and most had heart disease, compared with those receiving traditional surgery. A study reported by Beggs et al. [26] indicated that angiographic embolization possesses a higher risk of postoperative re-bleeding compared with surgery, but it does not affect the mortality rate.

Our study showed that the rate of re-bleeding was 2.92% (87/2977), lower than that reported in previous studies [8,27]. This might be related to the lower proportion of patients aged over 80 years old in this study. The proportion of patients with comorbidities was only 14.41%. The proportion of patients receiving a blood transfusion was also lower than that reported in previous studies. The study by Restellini et al. [28] showed that blood transfusions lead to an increase in the risk of re-bleeding but are unrelated to mortality. Studies reporting the mechanisms that lead to re-bleeding are rare. Re-bleeding may be caused by the disruption of a hypercoagulable state by a blood transfusion due to the elevation of coagulation factor VIII concentration after gastrointestinal bleeding; additionally, citrate as an anticoagulant may lead to further bleeding [29,30]. Previous studies have rarely focused on comorbidity in NVUGIB, but our study showed that 1.81% (54/2977) of patients developed comorbidities, of which pneumonia was the most common, followed by kidney failure.

A previous study in the USA [31] showed that the lengths of hospitalization for patients with and without comorbidities were 4.4 days and 2.7 days, respectively, while the hospitalization cost was USD 5632 (equivalent to RMB 46 182.40 based on the currency exchange rate in 2004) and USD 3402 (RMB 27 896.40), respectively. In this study, the median length of hospitalization was 8 days (IQR, 5–11 days) and the average hospitalization cost was RMB 17 470±51 752. The relative hospitalization cost was inversely proportional to the length of hospitalization, which may be related to differences in the medical pricing system. Our study showed that the mortality rate was 1.71%, which was significantly lower than that reported by previous studies [1–3]. A further analysis indicated that this might be due to a higher proportion of patients aged below 60 years, accounting for nearly 60%. Meanwhile, patients with peptic ulcer also accounted for a higher proportion. Jairath [32] reported that the greater difference in the mortality rates of NVUGIB reported worldwide was mainly due to the different research methods and populations in the studies. Multivariate studies found that age ≥80 years, admission to the emergency ward, systolic blood pressure of 50 mmHg, the presence of 2 or more comorbidities, and re-bleeding led to a significant increase in the mortality risk, while emergency endoscopy can reduce the rate of mortality.

Through this study, we found that NVUGIB exhibits a declining trend in China, but the rate of endoscopic therapy for high-risk peptic ulcer still needs to be improved. The drug discontinuation
period for patients using anti-platelet drugs while having gastrointestinal bleeding was longer than that in other countries. Patients admitted into the emergency ward have a higher risk of mortality and a lower rate of emergency endoscopy compared with patients admitted into the general wards and ICU. However, the proportions undergoing surgery and angiographic embolization are still low. The present study also has a few limitations. Firstly, we only described the non-variceal upper-gastrointestinal bleeding for the Chinese patients, but not for the other populations, which is also a limitation of this study. Secondarily, we analyzed the statistical results of a multi-center database, and there were a few limitations and bias in the data. Therefore, in a subsequent study, we would adjust the data and avoid the bias. Thirdly, each country has its own health insurance system, as well as cost effectiveness, but we did not discuss this point. We would also consider the health insurance system in a future study.

Conclusions

In China, peptic ulcer was still the most common cause of non-variceal upper-gastrointestinal bleeding (NVUGIB), but there was declining trend in the annual constituent ratio. Therefore, clinicians must suspect peptic ulcer in patients with high-risk factors associated with peptic ulcer.

Conflict of Interest

None.

References:

1. Barkun AN, Bardou M, Kuipers EJ et al: International Consensus Upper-Gastrointestinal Bleeding Conference Group. International consensus recommendations on the management of patients with non-variceal upper-gastrointestinal bleeding. Ann Intern Med, 2010; 152: 101–13
2. Jiang HH, Liu HL, Xiao YH et al: Video-assisted anal fistula treatment (VAAFT) for complex anal fistula: A preliminary evaluation in China. Med Sci Monit, 2017; 23: 2065–71
3. Blatchford Q, Murray WR, Blatchford M. A risk score to predict need for treatment for upper-gastrointestinal haemorrhage. Lancet, 2000; 356: 1318–21
4. Bielecker E. Diagnosis and therapy of non-variceal upper-gastrointestinal bleeding. World J Gastrointest Pharmacol Ther, 2015; 6: 172–82
5. Hearnshaw SA, Logan RF, Lowe D et al: Acute upper-gastrointestinal bleeding in the UK: Patient characteristics, diagnoses and outcomes in the 2007 UK audit. Gut, 2011; 60: 1327–35
6. Khamaysi I, Grahnke IM: Acute upper-gastrointestinal bleeding (UGIB), initial evaluation and management. Best Pract Res Clin Gastroenterol, 2013; 27: 633–38
7. Sung JJ, Chan FK, Chen M et al: Asia-Pacific Working Group consensus on non-variceal upper-gastrointestinal bleeding. Gut, 2011; 60: 1170–77
8. Leonidatis GI, Sharma VK, Howden CW: Proton pump inhibitor treatment for acute peptic ulcer bleeding. Cochrane Database Syst Rev, 2006; 1: CD002094
9. Mungan Z. An observational European study on clinical outcomes associated with current management strategies for non-variceal upper-gastrointestinal bleeding (ENERGIB-Turkey). Turk J Gastroenterol, 2012; 23: 463–77
10. Fonseca J, Alves CC, Neto R et al: Non-variceal upper gastrointestinal bleeding in Portugal: A multicentric retrospective study in twelve Portuguese hospitals. Gastroenterol Hepatol, 2012; 35: 377–85
11. Zeltoun JD, Rosa-Hézode J, Chrysostolis A et al: Epidemiology and adherence to guidelines on the management of bleeding peptic ulcer: A prospective multicenter observational study in 1140 patients. Clin Res Hepatol Gastroenterol, 2012; 36: 227–34
12. Yamaguchi O, Sakata Y, Tsuruoka N et al: Characteristics of patients with non-variceal upper-gastrointestinal bleeding taking antithrombotic agents. Dig Endosc, 2015; 27: 30–36
13. Tsol KK, Ma TK, Sung JJ: Endoscopy for upper-gastrointestinal bleeding: How urgent is it? Nat Rev Gastroenterol Hepatol, 2009; 6: 463–69
14. Taha AS, Kelly C, McCloskey C et al: Upper-gastrointestinal bleeding in hospital inpatients: The role of antithrombotic drugs. Postgrad Med J, 2014; 90: 429–33
15. Szuza M, Pasternak A: Upper non-variceal gastrointestinal bleeding, review the effectiveness of endoscopic hemostasis methods. World J Gastrointest Endosc, 2015; 7: 1088–95
16. Wysocki JD, Srivastav S, Winstead NS: Nationwide analysis of risk factors for mortality and time to endoscopy in upper-gastrointestinal haemorrhage. Aliment Pharmacol Ther, 2012; 36: 30–36
17. Trawick EP, Yachimski PS: Management of non-variceal upper-gastrointestinal tract hemorrhage: Controversies and areas of uncertainty. World J Gastroenterol, 2012; 18: 1159–65
18. Chiu PW: Second look endoscopy in acute non-variceal upper-gastrointestinal bleeding. Best Pract Res Clin Gastroenterol, 2013; 27: 905–11
19. Tsol KK, Chiu PW, Chan FK et al: The risk of peptic ulcer bleeding mortality in relation to hospital admission on holidays: A cohort study on 8,222 cases of peptic ulcer bleeding. Am J Gastroenterol, 2012; 107: 405–10
20. Bor S, Dalgl I, Sarer B et al: A retrospective study demonstrating properties of non-variceal upper-gastrointestinal bleeding in Turkey. Turk J Gastroenterol, 2011; 22: 249–54
21. Chen S, Xie S, He W et al: Beneficial effect of beraprost sodium plus aspirin in the treatment of acute ischemic stroke. Med Sci Monit, 2017; 23: 4401–7
22. Dehghanian SM, Haghighat M, Imanieh MH et al: Upper-gastrointestinal bleeding in children in Southern Iran. Indian J Pediatr, 2009; 76: 635–38
23. Villanueva C, Coloso A, Bosch A et al: Transfusion strategies for acute upper-gastrointestinal bleeding. N Engl J Med, 2013; 368: 11–21
24. Sildrogi O, Muasher J, Arslan B et al: Outcomes of patients with acute upper-gastrointestinal non-variceal hemorrhage referred to interventional radiology for potential embolotherapy. J Clin Gastroenterol, 2014; 48: 687–92
25. Ripoll C, Bañares R, Beceiro I et al: Comparison of transcatheter arterial embolization and surgery for treatment of bleeding peptic ulcer after endoscopic treatment failure. J Vasc Interv Radiol, 2004; 15: 447–50
26. Beggs AD, Dilworth MP, Powell SL et al: A systematic review of transarterial embolization versus emergency surgery in treatment of major non-variceal upper-gastrointestinal bleeding. Clin Exp Gastroenterol, 2014; 7: 93–104
27. Elakili R, Reda MA, Abdelhakam SM et al: Causes and outcome of upper-gastrointestinal bleeding in emergency endoscopy unit of AinShams University Hospital. J Egypt Soc Parasitol, 2011; 41: 455–67
28. Restellini S, Kherad O, Jairath V et al: Red blood cell transfusion is associated with increased re-bleeding in patients with non-variceal upper-gastrointestinal bleeding. Aliment Pharmacol Ther, 2013; 37: 316–22
29. Blair SD, Jarvin SB, McCollum CH et al: Effect of early blood transfusion on gastrointestinal haemorrhage. Br J Surg, 1986; 73: 783–85
30. Kawaguchi K, Kurumi H, Takeda Y et al: Management for non-variceal upper-gastrointestinal bleeding in elderly patients: The experience of a tertiary university hospital. Ann Trans Med, 2017; 5: 181
31. Adam V, Barkun A: Estimates of costs of hospital stay for variceal and non-variceal upper-gastrointestinal bleeding in the United States. Value Health, 2008; 11: 1–3
32. Jairath V, Martel M, Logan RF et al: Why do mortality rates for non-variceal upper-gastrointestinal bleeding differ around the world? A systematic review of cohort studies. Can J Gastroenterol, 2012; 26: 537–43